The Laboratory implements the most innovative diagnostic procedures for continuous improvement in the characterization of oncohematologic diseases for which an integrated clinical, hematologic, morphologic, hematopathologic, immunophenotypic, molecular-cytogenetics, next generation sequencing tools and epigenetic studies are used to pinpoint prognostic and predictive biomarkers. The laboratory is JACIE accredited for cell manipulation, AIFA and for performing diagnostic tests required for phase I clinical trials, and GenomicQualityAssessment, and it is a reference Center of the GIMEMA National Network for the diagnosis and treatment of acute leukemia. The main fields of research are represented by the genomic and epigenetic characterization of Acute Lymphoblastic and Myeloblastic Leukemias, Myelodysplastic Syndromes, Chronic Myelo- and Lympho- Proliferative Neoplasms, Hodgkin and Non-Hodgkin Lymphomas, and Hairy Cell Leukemia. We have also developed a line of research in post-transplant immunologic reconstitution and cell therapy, such as immunotherapy and CAR-T. The laboratory is also a reference Center for Congenital and Acquired Immunodeficiencies and Germline Predisposing Conditions, for which enables a precise molecular diagnosis through the application of custom target NGS panels. Translational research is linked in real time to diagnostics, in a continuous osmosis between the Departments of Hematology/DH and Laboratories. Therefore, the University component is relevant and the contribution to diagnosis decisive. The importance of a set of multidisciplinary laboratories that interface and operate in an integrated constitutes the added value for the real-time initiation of rapid and accurate diagnostic pathways, in each individual patient, in order to implement: 1) precise prognostic stratification of the patient; 2) make the best treatment choice in relation to the biological characteristics of the disease; 3) schedule continuous monitoring.